Needham Reiterates Buy Rating on Ionis Pharmaceuticals (IONS) on TRYNGOLZA approval
Tweet Send to a Friend
Needham analyst Chad Messer reiterated a Buy rating and $60.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).The analyst commented: "IONS ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
